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Abstract Previous studies have shown that bispecific
antibodies that target both CD20 and CD22 have in vivo
lymphomacidal properties. We developed a CD20-CD22
bispecific antibody (Bs20x22) from anti-CD20 and the
anti-CD22 monoclonal antibodies (mAb), rituximab and
HB22.7, respectively. Bs20x22 was constructed using
standard methods and was shown to specifically bind
CD20 and CD22. In vitro cytotoxicity assays showed that
Bs20x22 was three times more effective than either parent
mAb alone and twice as effective as a combination of both
parent mAb used at equimolar concentrations. Bs20x22
was also nearly four times more effective at inducing
apoptosis than either mAb alone. Examination of the
MAPK and SAPK signaling cascades revealed that
Bs20x22 induced significantly more p38 phosphorylation
than either mAb alone. In an in vivo human NHL xenograft
model, treatment with Bs20x22 resulted in significantly
greater tumor shrinkage and improved overall survival
when compared to either mAb alone or treatment with a
combination of HB22.7 and rituximab. The effect of the
initial tumor volume was assessed by comparing the effi-
cacy of Bs20x22 administered before xenografts grew
versus treatment of established tumors; significantly,
greater efficacy was found when treatment was initiated
before tumors could become established.
Keywords CD22  Lymphoma  Monoclonal antibody 
Diabody  Bispecific
Introduction
Approximately 250,000 people in the United States have
non-Hodgkin’s lymphoma (NHL), an 80% increase since
1970; NHL is the sixth most common cause of cancer-
related deaths in the United States [1]. NHL is a hetero-
geneous group of malignancies, the majority of which are
of B-lymphocyte origin (B-NHL). While standard cyto-
toxic chemotherapy is initially effective, resistance often
develops and the dose is often limited by toxicity [2, 3].
MAb-based therapy has enormous promise. The chi-
meric anti-CD20 mAb, rituximab, produces overall and
complete remission rates of 50 and 10%, respectively, in
patients with relapsed follicular NHL [4]. Rituximab is also
used in combination with several cytotoxic chemotherapy
regimens for both indolent and aggressive NHL and its
addition has led to improvements in overall survival [5].
Despite these advances, the majority of patients with NHL
eventually succumb to their disease. Because of the safety
and efficacy of mAbs like rituximab, new mAbs are being
tested to see if they are effective, synergistic with ritux-
imab, or useful against drug-resistant NHL.
CD22 is a B-lymphocyte-specific glycoprotein adhesion
molecule that can bind multiple types of hematopoietic cells
and transduces signals to the cell’s interior, resulting in a
cascade of phosphorylation events [6–8]. Nearly all mature
B-cells express CD22, although it disappears upon differ-
entiation into plasma cells. Most B-NHL express CD22
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[9–11], making CD22 a promising therapeutic target. The
extracytoplasmic portion of CD22 contains seven Ig-like
domains [7]. The two amino-terminal Ig domains mediate
cell adhesion to sialic-acid bearing ligands [12–14].
Anti-CD22 mAbs, such as HB22.7, that bind the two amino-
terminal Ig domains of CD22 and specifically block the
interaction of CD22 with its ligand induce proliferative
responses in primary B-cells, but apoptotic responses in
neoplastic B-cells [8, 15]. In contrast, anti-CD22 mAbs that
do not block ligand binding have only modest functional
effects [15]. We previously characterized several anti-CD22
mAbs that have unique signaling properties, pro-apoptotic
effects, and significant in vivo lymphomacidal capacity [16].
The combination of epratuzumab (anti-CD22) and rit-
uximab (anti-CD20) is efficacious [17–20]; however, this
combination must be administered sequentially, greatly
increasing the infusion time needed to treat a patient. This
makes a bispecific antibody (BsAb) that simultaneously
targets both CD20 and CD22 an attractive alternative to the
use of two different mAb. BsAbs can be designed to cross-
link two antigens on the same cell type, such as CD20 and
CD22 on B-NHL. CD20/CD22 BsAbs have been previ-
ously characterized, tested, and found to be promising
against NHL [25, 26]. These BsAbs use veltuzumab (anti-
CD20) and epratuzumab (anti-CD22) as a platform. In
contrast, we constructed a BsAb (Bs20x22) using ritux-
imab (anti-CD20) and HB22.7 (anti-CD22). The choice of
which anti-CD22 mAb to use is critical. We previously
demonstrated that anti-CD22 mAbs that block CD22 ligand
binding have greater efficacy than those that do not block
ligand binding [27]. Epratuzumab is rapidly internalized
into NHL cells and causes CD22 phosphorylation, but does
not block CD22 ligand binding, does not initiate CD22-
mediated signal transduction or apoptosis, and does not
demonstrate any direct cytotoxic or cytostatic effects [28].
In contrast, HB22.7 does block CD22 ligand binding, ini-
tiates CD22-mediated signal transduction, demonstrates
direct cytotoxic effects and has been found to improve
survival and decrease tumor volume in a human NHL
xenograft mouse model [16, 27, 29].
Herein, we describe the construction of a CD20/CD22-
targeted BsAb (Bs20x22) using a rituximab/HB22.7 platform,
its cell-binding characteristics, induced signaling patterns, and
pre-clinical efficacy in a human NHL xenograft model.
Materials and methods
Materials
The following materials were used: Sephadex G-25, Super-
dex 200, iodoacetamide, o-phenylenedimaleimide (PDM),
2-mercaptoethanol, sodium acetate, sodium orthovanadate,
2-glycerophosphate, bovine serum albumin (BSA), Tween-
20, CelLytic M lysis buffer, dimethylformamide (DMF),
Coomassie Brilliant Blue R, protease inhibitor cocktail
tablets and ethylenediaminetetraacetic acid (EDTA) (Sigma
Chemical Co.,St. Louis, MO), goat anti-mouse immuno-
globulins fluorescein conjugate (goat anti-mouse Ig-FITC)
(Biosource, Camarillo, CA), mouse anti-human IgG
(H ? L) Texas Red conjugate (Rockland Immunochemi-
cals; Gilbertsville, PA), anti-phospho-JNK, anti-JNK, anti-
phospho-ERK1/2, anti-ERK1/2, anti-phospho-p38, and
anti-p38 antibodies (Cell Signaling Technology, Danvers,
MA), anti-mouse HRP antibody (Dako North America, Inc,
Carpentaria, CA), polycaspases FLICA (FAM-VAD-FMK)
kit (Immunochemistry Technologies, LLC, Bloomington,
MN), BCATM protein assay kit, Silver SNAP II Stain Kit, and
ImmunoPure F(ab’)2 Preparation Kit (Pierce, Rockford, IL),
RPMI 1640 medium, DMEM medium, penicillin–strepto-
mycin and fetal bovine serum (FBS) (Life Technologies,
Carlsbad, CA), Rituximab (Rituxan) (Genentech (South San
Francisco, CA). The anti-CD22 mAb, HB22.7, was purified
from ascites and has been previously characterized [8]. All
chemicals were of analytical grade purity.
Cell lines
The CD20/CD22 double positive human Burkitt’s B-cell
lymphoma lines, Raji (ATCC CCL-86) and Ramos (ATCC
CRL-1596), and the CD20/CD22 double negative human
embryonic kidney cell line 293T (ATCC CRL-11268) were
purchased from American Type Culture Collection
(Rockville, MD). All cells were thawed and grown in
RPMI-1640 (Raji, Ramos) or DMEM (293T) supplemented
with 10% FBS, 50 units/ml penicillin G, and 50 lg/ml
streptomycin sulfate. Cells were maintained in tissue cul-
ture flasks at 37C in 5% CO2 and 90% humidity. After two
passages, multiple vials were re-frozen and stored in liquid
nitrogen for future use. Fresh vials of cells are periodically
thawed and used for in vitro experiments to ensure that
changes to cells have not occurred over time/passages in
culture. For xenograft studies, a fresh vial of Raji cells was
thawed 7–10 days before tumor cell implantation.
Bs20x22 construction
F(ab’)2 fragments of rituximab and HB22.7 were made
using ImmunoPure F(ab’)2 Preparation Kit (Pierce)
according to manufacturer’s instructions. For quality con-
trol, protein containing fractions were run on a 10% SDS–
PAGE gel under non-reducing conditions and silver stained
using Silver SNAP II Stain Kit (Pierce). F(ab’)2 containing
fractions were pooled and concentrated using a 10,000
MWCO centrifugal filter (Millipore). Each F(ab’)2 was
reduced to F(ab)-thiol by adding 2-mercaptoethanol to a
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final concentration of 20 mM at 30C for 30 min. Samples
were chilled on ice and then passed over chilled Sephadex
G25 columns equilibrated in 50 mM sodium acetate/
0.5 mM EDTA pH 5.3. Protein-containing fractions were
pooled. The HB22.7 Fab-thiol was then maleimidated for
30 min in a methanol ice bath by addition of  volume of
pre-chilled 12 mM o-PDM (dissolved in DMF). HB22.7-
maleimidated-Fab was then passed over a chilled Sephadex
G25 column equilibrated in 50 mM sodium acetate/
0.5 mM EDTA pH 5.3. Protein-containing fractions were
pooled and immediately added to rituximab-thiol-Fab in a
1:1 molar ratio. The reaction was placed under a constant
stream of nitrogen gas and stirred gently for 18 h at 4C.
The pH was adjusted to pH 8.0 using 1 M Tris–HCl pH
8.0, followed by the addition of 2-mercaptoethanol to a
final concentration of 20 mM. The reaction was incubated
for 30 min at 30C and then alkylated by adding iodo-
acetamide to a final concentration of 25 mM. The mixture
was then passed over a Superdex 200 column equilibrated
in PBS pH 7.4, and fractions were collected. Individual
fractions were run on 10% SDS–PAGE gels under non-
reducing conditions and stained with Coomassie Brilliant
Blue (Sigma) or Silver Snap II Kit (Pierce). F(ab’)2 con-
taining fractions (Bs20x22) were identified and pooled.
Cell-binding studies
The first set of binding studies was performed on 293T cells
(CD20/CD22 negative) transfected with CD20 or CD22.
Transfection was performed using a standard calcium
phosphate-mediated transfection protocol. Cells were used
for binding studies 24–48 h after transfection. CD20-trans-
fected or CD22-transfected cells (0.5 9 106 per sample)
were trypsinized, washed twice in FACS buffer (PBS sup-
plemented with 0.2% FBS), and stained with HB22.7, rit-
uximab, or Bs20x22 (5 lg in 100 lL FACS buffer). As
controls, untransfected cells were also stained with HB22.7,
rituximab, or Bs20x22 in the same manner. Cells were
incubated for 20 min on ice and then washed 4 times with
FACS buffer. Cells were stained with secondary antibodies
(1 lg in 100 lL FACS buffer) as follows: HB22.7-treated
samples were stained with goat anti-mouse Ig-FITC, ritux-
imab-treated samples were stained with goat anti-human
IgG-FITC, and Bs20x22-treated samples were stained with
either goat anti-mouse Ig-FITC (to detect HB22.7 compo-
nent) or goat anti-human IgG-FITC (to detect rituximab
component). As additional controls, CD20-transfected,
CD22-transfected, and untransfected cells were treated with
secondary antibodies only (no HB22.7, rituximab, or
Bs20x22 staining). Cells were incubated on ice for 15 min
and then washed 4 times in FACS buffer. Images were
acquired by fluorescence microscopy (Olympus Motorized
Reflected Fluorescence System BX61).
The second set of binding studies was performed using
CD20/CD22 double positive Raji and Ramos cells. Cells
(0.5 9 106 per sample) were washed and stained with
HB22.7, rituximab, and Bs20x22 as described earlier.
Secondary antibodies used in this experiment were as fol-
lows: HB22.7-treated samples were stained with goat anti-
mouse Ig-FITC, rituximab-treated samples were stained
with goat anti-human IgG-TxRd, and Bs20x22-treated
samples were treated with either goat anti-mouse Ig-FITC
(to detect HB22.7 component) or goat anti-human IgG-
TxRd (to detect rituximab component). As additional
controls, cells were treated with secondary antibodies only
(no HB22.7, rituximab, or Bs20x22). Images were acquired
by fluorescence microscopy.
In vitro cytotoxicity assay
Raji or Ramos cells (2–2.5 9 104 per sample) were plated
on triplicate in 96-well round bottom plates in a volume of
100 lL per well. Cells were treated for 1 h with HB22.7,
rituximab, HB22.7 plus rituximab, or Bs20x22 to final
concentrations of 0, 0.005, 0.05, 0.5, 5, 50, 100, or 200
lg/mL. Control cells received media only. After treatment,
plates were washed 3 times in media and then incubated at
37C in 5% CO2 and 90% humidity for 5 days. Viability was
assessed by trypan blue exclusion; results were expressed as
% of control (untreated cells).
In vitro apoptosis assay
Raji or Ramos cells (1 9 106) were plated in a volume of
1 mL per well. Cells were treated with HB22.7 (40 lg/mL),
rituximab (40 lg/mL), HB22.7 plus rituximab (40 lg/mL per
mAb for a total of 80 lg/mL), or Bs20x22 (80 lg/mL).
Control cells received media only. All samples were plated in
triplicate. Cells were incubated at 37C in 5% CO2 and 90%
humidity for 4 h. Cells were then washed and stained with
the Polycaspases FLICA (FAM-VAD-FMK) kit (Immuno-
chemistry Technologies, LLC) according to manufacturer’s
instructions. Cells were also stained with Hoechst stain and
propidium iodide (included in the kit) according to instruc-
tions. Cells were then analyzed by fluorescence microscopy
(Olympus Motorized Reflected Fluorescence System
BX61). Cells exhibiting positive propidium iodide staining
(dead cells) were excluded from further analysis. In each
209 field, the total number of cells (positive Hoechst stain)
and the number of apoptotic cells (positive FAM-VAD-FMK
stain) were counted. Three fields were counted for each
sample. The percentage of apoptotic cells was calculated by
dividing the number of apoptotic cells in a given field by the
total number of cells in that field. Results were graphed as
percentage of control (% apoptotic cells treated/% apoptotic
cells untreated).
Cancer Immunol Immunother (2011) 60:771–780 773
123
Western blotting
Ramos cells (2 9 107 per treatment) were treated with
one of the following: rituximab (100 lg/mL), HB22.7
(100 lg/mL), or Bs20x22 (100 lg/mL) in growth media.
Two different preparations of Bs20x22 (prepared approx-
imately 4 months apart) were tested. As a positive control,
one group of cells was treated with anti-IgM (50 lg/mL).
Untreated cells were used as a negative control. Cells were
treated for 15 min at 37C. After treatment, cells were
centrifuged (400g) and cell pellets resuspended in 125 lL
of Cell Lytic M lysis buffer supplemented with a protease
inhibitor cocktail tablet, sodium orthovanadate, and
2-glycerophosphate. Cells were lysed on ice for 30 min
with occasionally vortexing. Lysates (50 lg protein per
lane) were run on a 10% SDS–PAGE gel, followed by
transfer to a nitrocellulose membrane. Membranes were
blocked for 1 h at room temperature in 5% BSA in TBS-T,
rinsed in TBS-T, and then incubated at 4C overnight
in primary antibodies (anti-phospho-JNK, anti-phospho-
ERK1/2, or anti-phospho p38) diluted 1:1,000 in 5% BSA
in TBS-T. Membranes were washed 3 times in TBS-T and
then incubated for 1 h at room temperature with anti-
mouse HRP conjugate diluted 1:10,000 in 5% BSA in
TBS-T. Membranes were washed 4 times in TBS-T and
then probed with Advanced ECL detection reagent. To
determine total JNK, ERK1/2, and p38 levels, after
detection of phospho proteins, each membrane was strip-
ped and then re-probed with either anti-JNK, anti-ERK1/2,
or anti-p38 antibodies (1:1,000 dilution).
Xenograft studies
Six- to eight-week–old female Balb/c nude mice were
obtained from Harlan Sprague–Dawley (Indianapolis, IN)
and maintained in micro-isolation cages under pathogen-
free conditions in the UC Davis animal facility. Three days
after whole body irradiation (400 rads), 0.5 9 106 Raji
cells were implanted subcutaneously on the left flank. One
day after tumor implantation, mice were randomly divided
into 5 groups (n = 6–8 per group): rituximab only, HB22.7
only, combination rituximab/HB22.7, Bs20x22, or PBS
(control). Mice were administered treatment on day 14, 21,
and 28 after tumor implantation. Each dose was 140 lg
(0.047 lmol) total mAb (thus, the combination group
received 70 lg of rituximab and 70 lg of HB22.7, for a
total of 140 lg). PBS was administered at a volume
equivalent to the volume received by the Bs20x22 group.
An additional group of mice (n = 8) were administered
Bs20x22 treatment on day 1, 7, and 14 after tumor
implantation (before tumors had time to become estab-
lished). All treatments were administered via the tail vein.
All xenograft studies were repeated using the same sample
size for validation and statistical purposes. Tumors were
measured twice per week using a caliper, and tumor vol-
umes were calculated using the equation: (length 9
width 9 depth) 9 0.52. Mice were euthanized when the
tumor reached 15 mm in any dimension or 1,500 mm3. For
statistical purposes, the volume prior to euthanasia was
carried forward until completion of the study.
Statistical analysis
In vitro cytotoxicity data and apoptosis data were analyzed
by a two-tailed, unpaired Student’s t-test. Tumor volume
data were analyzed using Kaplan–Meier curves. For this
analysis, an ‘‘event’’ was defined as tumor volume reaching
400 mm3 or greater. Each individual mouse was ranked as
a 1 (event occurred) or a 0 (event did not occur) and the
time to event (in days) was determined. When an indi-
vidual was ranked as 0 (event did not occur), a time to
event of 88 days (number of days in the 12.5 week study)
was recorded. Chi-squared and P values were determined
by the Log-rank test. All statistical analysis was per-
formed using GraphPad Prism software (San Diego, CA).
A P value of \0.05 was considered significant.
Results
Bs20x22 exhibits cell binding similar
to its parent mAbs
To determine if the CD20/CD22 bispecific antibody
(Bs20x22) maintained binding characteristics similar to the
parent mAbs, 293T cells were transfected with either CD20
or CD22 and stained with Bs20x22 or a parent mAb.
Bs20x22 exhibited the same staining as rituximab on
CD20-transfected cells (Fig. 1a, b) and the same stain-
ing as HB22.7 on CD22-transfected cells (Fig. 1c, d).
Untransfected 293T cells showed no rituximab, HB22.7, or
Bs20x22 staining (data not shown). On CD20/CD22-posi-
tive Ramos cells, Bs20x22 also exhibited the same staining
as each parent mAb (Fig. 1 e, f). Staining results were
verified in the CD20/CD22-positive cell line, Raji.
Bs20x22 exhibits greater in vitro cytotoxicity
than the parent mAbs
The effect of Bs20x22 on in vitro cell viability was then
assessed. Raji cells were treated with each parent mAb
alone, combination rituximab plus HB22.7, or Bs20x22
for 1 h, and then washed; cell viability was assessed
5 days later. As shown in Fig. 2a, both Bs20x22 and the
rituximab plus HB22.7 combination demonstrated greater
cytotoxicity than either parent mAb alone. In addition,
774 Cancer Immunol Immunother (2011) 60:771–780
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Bs20x22 was more cytotoxic than higher doses of the
rituximab/HB22.7 combination (Fig. 2a). At the 50, 100,
and 200 lg/mL doses, Bs20x22 treatment resulted in 28,
16, and 11% cell viability, respectively, compared with
combination rituximab/HB22.7-treated cell viabilities of
35, 31, and 27%. Similar results were also seen using
Ramos cells (data not shown). To determine if the
increase in cytotoxicity was due to apoptosis, Raji and
Ramos cells were treated as described earlier and apop-
tosis was assessed using a polycaspase FLICA kit. The
percent of Raji and Ramos cells that underwent apoptosis
was greatest for Bs20x22 treatment (78 and 74%) com-
pared with combination rituximab plus HB22.7 (45 and
43%), rituximab (35 and 34%), and HB22.7 (24 and 22%)
(Fig. 2b).
Bs20x22 activates p-38 to a greater degree
than either parent mAb
To determine if Bs20x22 stimulated similar signaling
pathways as the parent mAbs, Ramos cells were treated
with rituximab, HB22.7, or Bs20x22 for 15 min, then
washed and lysed. The lysates were analyzed by Western
blot for phosphorylation/activation of MAP kinases p-38,
JNK, and ERK1/2. Cross-linking the B-cell receptor (BCR)
with anti-IgM was the positive control. Treatment with
Fig. 1 Transfected 293T or
Ramos cells were stained with
either rituximab, HB22.7, or
Bs20x22, then washed and
stained with the appropriate
anti-human or anti-mouse
fluorescent mAb. a CD20-
transfected 293T cells ?
rituximab. b CD20-transfected
293T cells ? Bs20x22.
c CD22-transfected 293T
cells ? HB22.7. d CD22-
transfected 293T cells ?
Bs20x22. e Ramos ?
Bs20x22 ? anti-human
Ig-TexasRed. f Ramos ?
Bs20x22 ? anti-mouse Ig-FITC
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Bs20x22 resulted in significant activation of p38, while
treatment with either parent mAb did not (Fig. 3). Neither
JNK nor ERK1/2 were activated by Bs20x22, rituximab, or
HB22.7.
Bs20x22 improves survival more than either parent
mAb
Nude mice bearing Raji xenografts were treated with rit-
uximab, HB22.7, combination rituximab plus HB22.7, or
Bs20x22 on days 14, 21, and 28 after tumor implantation.
As shown in Fig. 4a, treatment with Bs20x22 resulted in
the smallest tumor volume of any group, although statis-
tical significance was achieved only for the Bs20x22 versus
control and the Bs20x22 versus HB22.7 comparisons
(Table 1). Mice treated with the combination of rituximab
and HB22.7 also had smaller tumor volumes than mice
treated with either parent mAb alone (Fig. 4a). By the end
of the study, Bs20x22-treated mice had tumors that were,
on average, 50% smaller than tumors from combination
rituximab/HB22.7-treated mice (Fig. 4a). As shown in
Fig. 4b, Bs20x22-treated mice exhibited the greatest
survival rate at the end of the study (88%) compared with
combination rituximab plus HB22.7 (75%), rituximab
(50%), HB22.7 (25%), and control (0%).
Previous studies with both HB22.7 and rituximab had
demonstrated greater efficacy when treating smaller tumor
volumes [16, 27, 29]; therefore, we compared pre-emptive
(prior to the development of visible tumors) Bs20x22
treatment (days 1, 7, and 14 post-implantation) to Bs20x22
treatment of established tumors (days 14, 21, and 28 post-
implantation). By the end of the study, mice treated pre-
emptively with Bs20x22 had tumors that were 89% smaller
than those in the established tumor-Bs20x22 treatment
group (Fig. 4c).
Discussion
Other groups have tested BsAbs that target CD20 and
CD22 using veltuzumab and epratuzumab, respectively,
and these BsAbs demonstrated enhanced efficacy when
compared to the parent mAbs [25, 26]. While the velt-
uzumab/epratuzumab bispecific mAb had enhanced in vitro
cytotoxicity, this was dependent upon hypercrosslinking
with a secondary antibody and this did not translate into
better survival when compared to the parent mAb in
in vivo. To improve cross-linking, a hexavalent veltuzu-
mab/epratuzumab-derived CD20/CD22 bispecific mAb
was developed and tested in the same in vitro and in vivo
models. The hexavalent antibody demonstrated enhanced
apoptotic induction, and this did translate into improved
survival (approximately 35–40%). However, the improved
survival depended upon host immune effector mechanisms.
This was demonstrated by the fact that the survival
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Fig. 2 Raji cells were treated with rituximab (filled triangle), HB22.7
(empty circle), combination rituximab/HB22.7 (empty square), or
Bs20x22 (filled circle) and assessed for cell viability (a). Raji and
Ramos cells were assessed for apoptotic induction (b). Error bars
represent the standard deviation *P value \ 0.02 (Bs20x22 vs
rituximab/HB22.7). **P value \ 0.01 (Bs20x22 vs rituximab/
HB22.7). ***P value \ 0.01 (Bs20x22 vs all groups)
Fig. 3 Ramos cells were treated with rituximab, HB22.7, or two
different preparations (labeled 1 and 2) of Bs20x22. MAP kinase
activation (p-38, JNK, ERK1/2) was analyzed by Western blot. Anti-
IgM was included as a positive control. This represents a consistent
and representative experiment, which was done in duplicate
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advantage was abrogated by NK cell depletion, which is
likely related to the fact that the hexavalent mAb contained
an intact antibody and Fc component. However, the choice
of anti-CD22 mAb is a critical one—different anti-CD22
mAbs exhibit distinct functional effects. The Tedder lab-
oratory mapped and characterized CD22 ligand–binding
domains using a panel of anti-CD22 mAbs and found that
several mAbs, such as HB22.7, completely blocked inter-
action with its ligand on all cell types examined, while
other anti-CD22 mAbs, such as HB22.27, exhibited no
blocking ability [12]. Subsequent studies used constructs
expressing specific deletions of CD22 Ig-like domains
(domains 1–4) to map where these mAbs bound within the
extracytoplasmic portion of CD22, and the two amino-
terminal domains (1 and 2) were found to be necessary for
mAb-dependent ligand blocking [30]. The pro-apoptotic
effects of these anti-CD22 mAbs were also studied, and
there was a significant induction of apoptosis after cross-
linking CD22 with the blocking mAb HB22.7 [8]. Little
induction of apoptosis was seen with the non-blocking
mAb, HB22.27, demonstrating the distinct functional
properties ligand blocking mAbs versus non-blocking
mAbs [8]. Additionally, ligand blocking anti-CD22 mAbs
are more effective than non-blocking anti-CD22 mAbs at
initiating CD22-mediated signal transduction [31]. These
studies demonstrate that ligand blocking anti-CD22 mAbs
are unique and functionally distinguishable from other anti-
B-cell and even other anti-CD22 mAb.
In vitro studies demonstrated that epratuzumab was
rapidly internalized into NHL cells and caused CD22
phosphorylation, but did not initiate CD22-mediated signal
transduction or apoptosis and did not demonstrate any
direct cytotoxic or cytostatic effects [28]. Epratuzumab
binds to the Ig-like domain 3 of CD22 [32], making it
unlikely than epratuzumab has ligand blocking properties.
In contrast, the HB22.7 anti-CD22 mAb, binds domains
1 and 2 and does exhibit ligand blocking properties. In a
pre-clinical NHL model, when HB22.7 was compared
with another anti-CD22 mAb (HB22.27) that similar to
epratuzumab, does not block CD22 ligand binding; HB22.7
had superior efficacy [13, 27]. The superior efficacy of
HB22.7 over the epratuzumab-like HB22.27 most likely
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Fig. 4 Mice bearing Raji NHL xenografts were treated with ritux-
imab (empty square), HB22.7 (empty triangle), combination ritux-
imab/HB22.7 (solid square), Bs20x22 (filled diamond), or PBS
control (empty diamond). Mice were assessed twice weekly for tumor
volume (a) and survival (b). Mice bearing Raji NHL xenografts were
treated with Bs20x22 before (‘‘pre-emptive’’, filled triangle) or after
(‘‘established’’, filled circle) tumors were established and compared
with untreated controls (filled squares) (c). Replicate experiments
were done with consistent results with the data presented representing
an analysis of all mice studied. A total of 16 mice pre-treatment group
were used with the error bars representing the standard deviation
Table 1 Xenograft statistics: Tumor volume data (from Fig. 4a)
were analyzed as described in ‘‘Materials and methods’’
Comparison Chi2 P value
Control vs. HB22.7 2.798 0.0944
Control vs. rituximab 2.561 0.1095
Control vs. HB22.7 ? rituximab 4.310 0.0379
Control vs. Bs20x22 8.532 0.0035
HB22.7 vs. rituximab 1.315 0.2515
HB22.7 vs. HB22.7 ? rituximab 1.887 0.1696
HB22.7 vs. Bs20x22 7.702 0.0055
Rituximab vs. HB22.7 ? rituximab 0.285 0.5933
Rituximab vs. Bs20x22 1.636 0.2009
Bs20x22 vs. HB22.7 ? rituximab 0.378 0.5385
The Chi2 and P value are shown for each comparison. Statistically
significant comparisons (P value \ 0.05) are shown in bold
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occurred because the lymphomacidal properties of HB22.7
depend upon the targeting of the specific CD22 epitope
(domains 1 and 2) bound by HB22.7. In addition, studies
by the Tedder laboratory have demonstrated that the CD22
ligand–binding domain is required for in vivo B-cell sur-
vival [33], which could explain why anti-CD22 mAbs that
bind to this ligand-binding domain have greater efficacy
than anti-CD22 mAbs that bind to non-ligand-binding
domains. For these reasons, we believe HB22.7 is a better
platform than epratuzumab for CD22-based BsAbs. We
constructed a CD20-CD22 BsAb (Bs20x22) using HB22.7
and rituximab as a platform and tested this BsAb in a pre-
clinical NHL model.
To determine if Bs20x22 maintained similar binding
characteristics as the parent mAbs, Ramos cells (CD20/
CD22 positive) and 293T cells transfected with either
CD20 or CD22 were stained with Bs20x22, rituximab, or
HB22.7. Ramos cells and CD20 transfected 293T cells
exhibited Bs20x22 staining that was equivalent to ritux-
imab (Fig. 1a, b, e). Similarly, Ramos cells and CD22
transfected 293T cells exhibited Bs20x22 staining that was
equivalent to HB22.7 (Fig. 1c, d, f). Un-transfected 293T
cells showed no rituximab, HB22.7, or Bs20x22 staining.
These results indicate that Bs20x22 exhibits specific
binding to both CD20 and CD22.
We next examined the in vitro cytotoxicity of Bs20x22.
Both Bs20x22 and the rituximab/HB22.7 combination
treatment demonstrated greater cytotoxicity than either
parent mAb alone at doses of 0.5 lg/mL or higher
(Fig. 2a). Bs20x22 was more cytotoxic than the rituximab/
HB22.7 combination treatment at lower doses. However, at
higher doses (100–200 lg/mL), Bs20x22 was significantly
more cytotoxic than the rituximab/HB22.7 combination
(P values \ 0.02 and \0.01, respectively) (Fig. 2a). This is
consistent with the in vivo levels of rituximab in patients
needed to achieve cytotoxic effects. To determine if this
increase in cytotoxicity was due to apoptosis, Raji and
Ramos NHL cells were treated as described earlier and
apoptosis was assessed using a polycaspases FLICA kit.
The percentage of apoptotic cells was significantly greater
(P \ 0.01) for Bs20x22 treatment in both Raji and Ramos
cells when compared with combination rituximab/HB22.7
treatment (Fig. 2b). Combination rituximab/HB22.7 treat-
ment did not significantly increase apoptosis over ritux-
imab or HB22.7 treatment alone (Fig. 2b) and suggests that
the Bs20x22 have apoptotic effects that are more potent
than either mAb alone.
We next began to examine the mechanism for the
enhanced in vitro cytotoxicity observed with Bs20x22
treatment. Both HB22.7 and rituximab activate the p38
signaling pathway, and it has been hypothesized that p38
activation may mediate cytotoxic effects. Therefore, the
ability of Bs20x22 to activate various signaling proteins
was compared with the parent mAbs. Western blot analysis
demonstrated that Bs20x22 activates p-38 to a much
greater extent that either parent mAb alone (Fig. 3). Longer
exposures revealed a relatively low level of p38 activation
with either parent mAb alone, which may be explained by
the fact that for the current study, the dose of each mAb
was much lower than those used in previous studies.
Examination of the ERK-1/2 and JNK signaling pathways
revealed that there was no differential activation of these
pathways with BS20x22.
We next sought to determine if the in vitro results
translated into an improvement in efficacy in vivo. Xeno-
graft bearing mice were treated with rituximab, HB22.7,
combination rituximab/HB22.7, or Bs20x22 on days 14,
21, and 28 after tumor implantation. Mice treated with
Bs20x22 had the smallest tumor volume of any group,
although comparisons between groups were only signifi-
cant for the Bs20x22 versus control and the Bs20x22
versus HB22.7 comparisons (Fig. 4a, Table 1). By the end
of the study, Bs20x22-treated mice had tumors that were,
on average, 50% smaller than tumors from combination
rituximab/HB22.7-treated mice (Fig. 4a). In addition to
smaller tumors, at the end of the study, Bs20x22-treated
mice exhibited the greatest survival rate of any group
(88%) compared with combination rituximab/HB22.7
(75%), rituximab (50%), HB22.7 (25%), and control (0%)
(Fig. 4b). This compares favorably to the survival seen in
the same xenograft model treated with the hexavalent
bispecific CD20/CD22 mAb [26]. Previous studies with
HB22.7 and rituximab have shown more robust tumor
volume reduction than that seen in this study [5, 16, 27, 29].
This can be explained by the fact that in order to maintain
equivalent total mAb dosing between all groups, and in
order to see any additive effects of rituximab/HB22.7
combination, less than optimal doses of rituximab and
HB22.7 were used in this study. Previous pre-clinical
studies with both rituximab and HB22.7 demonstrated
superior efficacy when used to treat smaller tumors or
when administered preemptively; therefore, we also com-
pared Bs20x22 treatment in a preemptive model versus an
established tumor model. Not surprisingly, mice treated
with preemptive Bs20x22 had tumors that were, on aver-
age, 89% smaller than those in the established tumor
Bs20x22 treatment group (Fig. 4c).
It is interesting to hypothesize how Bs20x22 exerts
its effects. Studies using veltuzumab/epratuzumab-based
CD20/CD22 BsAbs showed that these BsAbs increased
antibody dependent cellular cytotoxicity (ADCC) but no
complement-dependent cytotoxicity (CDC) when com-
pared to parent mAbs [25, 26]. In fact, all in vivo activity
was abrogated by NK cell depletion. Cross-linking with
these BsAbs causes translocation of CD20, CD22, and
BCR into lipid rafts and the effects of BsAb-induced
778 Cancer Immunol Immunother (2011) 60:771–780
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localization of BCR into lipid rafts resembles that caused
by anti-IgM [25]. In addition, CD22 undergoes internali-
zation once bound by ligand, while CD20 does not [33]. By
cross-linking CD22 to CD20, a CD20/CD22 BsAb prevents
CD22 internalization [25], which likely affects downstream
signaling. Since our Bs20x22 uses rituximab and HB22.7,
the mechanisms of Bs20x22’s actions may differ from
those of veltuzumab/epratuzumab-based BsAbs. However,
it is clear that no matter what the platform, BsAbs exhibit
novel mechanisms when compared to their parent mAbs.
These mechanisms are an active area of exploration.
Our data suggest that Bs20x22 is a more efficacious
treatment for NHL than is combination rituximab/HB22.7
and possibly better than the veltuzumab/epratuzumab-based
BsAbs. It is also important to note that Bs20x22 does not
utilize an intact antibody/Fc and thus is likely not dependent
on host immune effector mechanisms. This may be important
in many lymphoma patients that are immunocompromised.
In addition, the use of a BsAb eliminates the need for
sequential administration of two separate mAbs, saving the
patient’s time. The NCI has recently approved and funded
the humanization of HB22.7 through the Rapid Access
Intervention Drug (RAID) Program. Given the pre-clinical
potential of Bs20x22, this humanized HB22.7 can be tested
in a new, humanized version of Bs20x22.
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